This article has been updated with additional information from Sarah Cannon Research Institute.Originally published July 2.

Extending an existing drug development research pact, AstraZeneca and Sarah Cannon Research Institute this week said they would work together to identify patients for drug development trials based on their genetic profiles.

For this collaboration, AstraZeneca will make its portfolio of oncology small molecule drugs available to SCRI. The drug developer has formed a team to partner with SCRI on the project.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.